Recurrence free survival as a putative surrogate for overall survival in phase III Trials of Curative – Intent Treatment of Colorectal Liver Metast...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter R. Araujo
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors R. Araujo1, P. Herman2, R. Riechelmann3
  • 1Barretos Cancer Hospital, Barretos, Brazil, /
  • 2Department of Gastroenterology, University of São Paulo, São Paulo, Brazil, /
  • 3Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, /

Abstract

Analysis of overall survival (OS) in phase III trials with low progressive malignancies is an issue hardly addressed since it demands large samples, great cost and longer follow-up. Gains in recurrence free survival (RFS) for initially resectable colorectal liver metastases (CRLM) have been demonstrated by phase III trials, but this has not been associated with improvements in OS in phase III trials, although, already suggested in meta-analyses. The objective of this systematic review was to verify whether RFS surrogates OS in phase III trials for resectable CRLM.

\r\n